Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped up prior to trading on Thursday. The stock had previously closed at $9.41, but opened at $10.0250. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.6150, with a volume of 3,694 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the company currently has an average rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. The stock’s 50-day moving average is $9.13 and its 200 day moving average is $9.21. The stock has a market capitalization of $16.36 billion, a PE ratio of 9.61, a P/E/G ratio of 3.45 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. As a group, equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.